Impact of empagliflozin on diabetic kidney disease

被引：1
|
作者：
Koya, Daisuke [1 ,2 ]
机构：
[1] Dept Diabetol Endocrinol Div Anticipatory Mol Foo, Kanazawa Medical Univers, Ishikawa, Japan
[2] Kanazawa Med Univ, Dept Diabetol & Endocrinol, Div Anticipatory Mol Food Sci & Technol, Uchinada, Ishikawa, Japan
来源：
JOURNAL OF DIABETES INVESTIGATION | 2017年 / 8卷 / 05期
关键词：
D O I：
10.1111/jdi.12615
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：658 / 660
页数：3
相关论文
共 50 条
  • [1] Empagliflozin Is Not Renoprotective in Non-Diabetic Rat Models of Chronic Kidney Disease
    Hojna, Silvie
    Kotsaridou, Zoe
    Vanourkova, Zdenka
    Rauchova, Hana
    Behuliak, Michal
    Kujal, Petr
    Kadlecova, Michaela
    Zicha, Josef
    Vaneckova, Ivana
    BIOMEDICINES, 2022, 10 (10)
  • [2] Diabetic kidney disease: impact of puberty
    Lane, PH
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2002, 283 (04) : F589 - F600
  • [3] Time to Invest in the Future: Assessing the Cost-Effectiveness of Empagliflozin in Diabetic Kidney Disease
    Khine, Annika
    Kwok, Jonas
    Lin, Eugene
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2022, 79 (06) : 780 - 782
  • [4] Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
    Judge, Parminder K.
    Staplin, Natalie
    Mayne, Kaitlin J.
    Wanner, Christoph
    Green, Jennifer B.
    Hauske, Sibylle J.
    Emberson, Jonathan R.
    Preiss, David
    Ng, Sarah Y. A.
    Roddick, Alistair J.
    Sammons, Emily
    Zhu, Doreen
    Hill, Michael
    Stevens, Will
    Wallendszus, Karl
    Brenner, Susanne
    Wallendszus, Karl
    Brenner, Susanne
    Cheung, Alfred K.
    Liu, Zhi-Hong
    Li, Jing
    Hooi, Lai Seong
    Liu, Wen Jiun
    Kadowaki, Takashi
    Nangaku, Masaomi
    Levin, Adeera
    Cherney, David
    Maggioni, Aldo P.
    Pontremoli, Roberto
    Deo, Rajat
    Goto, Shinya
    Rossello, Xavier
    Tuttle, Katherine R.
    Steubl, Dominik
    Massey, Dan
    Landray, Martin J.
    Baigent, Colin
    Haynes, Richard
    Herrington, William G.
    LANCET DIABETES & ENDOCRINOLOGY, 2024, 12 (01): : 51 - 60
  • [5] Empagliflozin in Patients with Chronic Kidney Disease
    Herrington, William G.
    Staplin, Natalie
    Wanner, Christoph
    Green, Jennifer B.
    Hauske, Sibylle J.
    Emberson, Jonathan R.
    Preiss, David
    Judge, Parminder
    Mayne, Kaitlin J.
    Ng, Sarah Y. A.
    Sammons, Emily
    Zhu, Doreen
    Hill, Michael
    Stevens, Will
    Wallendszus, Karl
    Brenner, Susanne
    Cheung, Alfred K.
    Liu, Zhi-Hong
    Li, Jing
    Hooi, Lai Seong
    Liu, Wen
    Kadowaki, Takashi
    Nangaku, Masaomi
    Levin, Adeera
    Cherney, David
    Maggioni, Aldo P.
    Pontremoli, Roberto
    Deo, Rajat
    Goto, Shinya
    Rossello, Xavier
    Tuttle, Katherine R.
    Steubl, Dominik
    Petrini, Michaela
    Massey, Dan
    Eilbracht, Jens
    Brueckmann, Martina
    Landray, Martin J.
    Baigent, Colin
    Haynes, Richard
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (02): : 117 - 127
  • [6] Empagliflozin in Patients with Chronic Kidney Disease
    Neuen, Brendon G.
    Fletcher, Robert
    Heerspink, Hiddo J. L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (24): : 2300 - 2302
  • [7] Emphysematous Kidney Related to the Use of Empagliflozin in a Diabetic Woman
    Echeverria, Pablo
    Saa, Julia
    Paz y Mino, Luis D.
    AACE CLINICAL CASE REPORTS, 2023, 9 (04): : 136 - 139
  • [8] Empagliflozin (Jardiance) for Chronic Kidney Disease
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2023, 65 (1689): : 183 - 184
  • [9] Impact of Lifestyle Modification on Diabetic Kidney Disease
    Chijoke Onyenwenyi
    Ana C. Ricardo
    Current Diabetes Reports, 2015, 15
  • [10] Impact of Lifestyle Modification on Diabetic Kidney Disease
    Onyenwenyi, Chijoke
    Ricardo, Ana C.
    CURRENT DIABETES REPORTS, 2015, 15 (09)
12345